Description of the medicine: Fludarabin
9-β-D- [Arabinofuranosyl-2-fluoroadenine 5ґ- (dihydrogen phosphate)].
Synonym: Fludara, Fludara.
Cytostatic substance, inhibiting ribonucleotide reductase and biosynthesis of DNA and proteins.
It is used for β-cell lymphocytic leukemia, non-Hodgkin's lymphoma (low degree of malignancy), mushroom mycosis, hairy cell leukemia, lymphomas.
Enter intravenously for 0.025 g (25 mg) per 1 m 2 of the body surface daily for 5 days every 28 days.
The injection solution is prepared ex tempore by injecting 2 ml of water for injection into the vial. The resulting solution is diluted in isotonic solution (0.9%) of water for injection: for bolus administration - in 10-20 ml; For infusion - in 100 ml (for 30 min).
Possible side effects: neutropenia, thrombocytopenia, anemia; Rarely - dyspepsia, gastric bleeding, peripheral neuropathy.
Contraindications: renal failure, decompensated hemolytic anemia, pregnancy, breast-feeding.
Form release: lyophilized powder in bottles of 0.05 g (50 mg).